Phenotypes Associated with This Genotype

Genotype
MGI:7467113

• Allelic Composition: Ctnna1^tm1Efu/Ctnna1^tm1Efu; Gt(ROSA)26Sor^{tm14(CAG-tdTomato)Hze}/Gt(ROSA)26Sor⁺; Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * C57BL/6NCrl * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

decreased angiogenesis ( J:328283 )

• slower growth of horizontal blood vessels in retina at age P3 during tamoxifen administration from age P1-P4

• slower growth of horizontal blood vessels in retina at age P9 after tamoxifen administration from age P1-P4

• delayed growth of vertical blood vessels in superficial retina vascular plexus at age P9 after tamoxifen administration from age P1-P

• lack of vertical secondary and tertiary vessels in retina at age P9 after tamoxifen administration from age P1-P4

• defects of vascular growth into deeper layers of retina at age P9 after tamoxifen administration from age P1-P4

• defects in periphery of superficial retina vascular plexus at age P13 after tamoxifen administration from age P6

• fewer vessels in retina OPL and minimal vessels in retina IPL at age P13 after tamoxifen administration from age P6

increased angiogenesis ( J:328283 )

• enlarged superficial vessels in retina at age P9 after tamoxifen administration from age P1-P4

• enlarged blood vessels in brain at age P9 after tamoxifen administration from age P1-P4

hemorrhage ( J:328283 )

• in eyes after tamoxifen administration from age P1-P4

impaired blood-brain barrier function ( J:328283 )

• extensive blood leakage in brain at age P9 after tamoxifen administration from age P1-P4

vision/eye

abnormal retina development ( J:328283 )

• slower growth of horizontal blood vessels at age P3 during tamoxifen administration from age P1-P4

• slower growth of horizontal blood vessels and enlarged superficial vessels at age P9 after tamoxifen administration from age P1-P4

• delayed growth of vertical blood vessels in superficial retina vascular plexus at age P9 after tamoxifen administration from age P1-P4

• lack of vertical secondary and tertiary vessels at age P9 after tamoxifen administration from age P1-P4

• defects of vascular growth into deeper layers at age P9 after tamoxifen administration from age P1-P4

• defects in periphery of superficial retina vascular plexus at age P13 after tamoxifen administration from age P6

• fewer vessels in OPL and minimal vessels in IPL at age P13 after tamoxifen administration from age P6

• increased blood vessel leakage at age P9 after tamoxifen administration from age P1-P4

persistence of hyaloid vascular system ( J:328283 )

• slower regression after tamoxifen administration from age P1-P4

microphthalmia ( J:328283 )

• after tamoxifen administration from age P1-P4

mortality/aging

postnatal lethality, complete penetrance ( J:328283 )

• most mice die by age P9 after tamoxifen administration from age P1-P4

• mice die by age P13-P14 after tamoxifen administration from age P6

nervous system

impaired blood-brain barrier function ( J:328283 )

• extensive blood leakage in brain at age P9 after tamoxifen administration from age P1-P4

growth/size/body

decreased body size ( J:328283 )

• after tamoxifen administration from age P1-P4

slow postnatal weight gain ( J:328283 )

• after tamoxifen administration from age P1-P4

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
exudative vitreoretinopathy		DOID:0050535	OMIM:PS133780	J:328283